5 results about "Cardiac Progenitor Cell" patented technology

The present application relates to a culture method and application of cardiac progenitor cells with myocardial and epicardial dual differentiation potential. Specifically, the present application provides cardiac progenitor cells with myocardial and epicardial dual differentiation potential, and provides a culture medium and culture method for inducing human pluripotent stem cells to differentiate into the dual potential cardiac progenitor cells, and further provides a method for differentiating the dual potential cardiac progenitor cells into myocardial cells and / or epicardial cells. The present application provides a new cell model for the development process and principle research of early cardiac lineage, and has a wide application prospect in the field of cell therapy and regenerative medicine related to heart diseases.

Animal cells, notably adult fibroblasts, are advantageously reprogrammed in direct lineage reprogramming methods using defined factors to produce proliferative and multipotent induced cardiac progenitor cells (iCPC). The iCPC thus produced can be differentiated under suitable differentiation conditions to cardiac lineage cells including cardiomyocytes, smooth muscle cells, and endothelial cells, as evidenced by expression of lineage specific markers. Sets of factors effective in combination to reprogram the fibroblasts can include a set that includes some or all of 5 factors (Mespl, Baf60c, Nkx2.5, Gata4, Tbx5), a set that includes some or all of 11 factors (Mespl, Mesp2, Gata4, Gata6, Baf60c, SRF, Isll, Nkx2.5, Irx4, Tbx5, Tbx20), a set that includes some or all of 18 factors (T, Mespl, Mesp2, Tbx5, Tbx20, Isll, Gata4, Gata6, Irx4, Nkx2.5, Handl, Hand2, Tbx20, Tbx18, Tip60, Baf60c, SRF, Hey2), and a set that includes some or all of 22 factors (T, Mespl, Mesp2, Tbx5, Tbx20, Isll, Gata4, Gata6, Irx4, Nkx2.5, Hand1, Hand2, Tbx20, Tbx18, Tip60, Baf60c, SRF, Hey2, Oct4, Klf4, Sox2, L-myc).

The invention relates to a myocardial progenitor cell and drug double-loaded hydrogel biological material and application thereof, and particularly provides a biological material compound which comprises an organic compound, living cells and a loading material, and the organic compound can induce expression of protease. The compound is used in the treatment process of myocardial infarction (MI), the functionality of transplanted cells is improved, and effective repair and functional recovery of damaged myocardium are promoted.

The invention discloses a method for preparing heart organoid, and relates to the technical field of organ preparation, and the method comprises the following specific steps: S1, stem cell amplification and homogenized embryoid body preparation; s2, specific induction of cardiac progenitor cells: culturing the embryoid body, driving the cells to differentiate to mesoderm, and culturing again to obtain progenitor cells; s3, cardiac field zoning and multi-lineage spontaneous differentiation: putting the progenitor cells into a culture system to induce spontaneous differentiation of the cells; s4, forming a three-dimensional self-assembly and cavity structure: transferring the differentiated tissue into a dynamic rotary culture system to form a layered organ; s5, electrophysiology maturation and function strengthening, wherein the obtained organoid is subjected to programmed electric pulse stimulation, and the highly-bionic heart organoid is obtained. Through a staged and multi-dimensional induction strategy, by simulating the time sequence and space microenvironment of human embryo heart development, stem cells are guided to form the organoid in a self-organizing manner, and the use universality of the prepared heart organoid is improved.

To provide a method for producing a cardiac muscle cell by using a receptor type tyrosine kinase inhibitor, and to provide a method for purifying the cardiac muscle cell.SOLUTION: A method for producing a cell population comprising cardiomyocytes, comprising the steps of: (1) culturing pluripotent stem cells in a medium for cardiomyocyte differentiation to obtain a cell population comprising cardiomyocytes or myocardial progenitor cells and other cells; and (2) culturing the cell population in the presence of a receptor tyrosine kinase inhibitor (excluding an EGF receptor inhibitor). And (2) a step of culturing the cell population.SELECTED DRAWING: None